Meeting
2020 ASCO Virtual Scientific Program
The efficacy and safety profile of anlotinib with etoposide plus cisplatin/carboplatin in treatment-naive extensive-stage small cell lung cancer(SCLC) patients: Results from a phase II single-arm trial.
Authors
Pengbo Deng
Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, China
Pengbo Deng , Huaping Yang , Cen Chen , Chengping Hu , Liming Cao , Qihua Gu , Jian An , Bin Li , Yongjun Tang , Jie Meng , Juntao Feng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9066)
DOI
10.1200/JCO.2020.38.15_suppl.9066
Abstract #
9066
Poster Bd #
259
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): The final results from a phase II single-arm trial.
First Author: Tiandong Kong
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Combination of hSTC810 and capecitabine therapy in metastatic colorectal cancer with resistance or intolerance to oxaliplatin and irinotecan-based chemotherapy: A single arm, phase 1b/2, multicenter study.
First Author: Jiwon Lee
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu